Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2002 Sep;129(3):541–548. doi: 10.1046/j.1365-2249.2002.01933.x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2002 Blackwell Science Ltd

PMC Copyright notice

Fig. 1 — Cellular components of bronchoalveolar lavage fluid (BALF) in dermatomyositis (DM)/polymyositis (PM) patients with corticosteroid-resistant and corticosteroid-sensitive interstitial pneumonitis (IP). Prior to corticosteroid therapy, BALF was obtained from DM/PM patients with corticosteroid-resistant IP (n = 6, ▪) and corticosteroid-sensitive IP (n = 16,) and from controls without IP including DM patients without IP (n = 12, □), and the number of total cells, lymphocytes, macrophages, neutrophils, and eosinophils in BALF was evaluated. Data are means ± SD in each group. Significant different from the mean values in controls without IP, *P < 0·05, **P < 0·005.

Inline graphic — Cellular components of bronchoalveolar lavage fluid (BALF) in dermatomyositis (DM)/polymyositis (PM) patients with corticosteroid-resistant and corticosteroid-sensitive interstitial pneumonitis (IP). Prior to corticosteroid therapy, BALF was obtained from DM/PM patients with corticosteroid-resistant IP (n = 6, ▪) and corticosteroid-sensitive IP (n = 16,) and from controls without IP including DM patients without IP (n = 12, □), and the number of total cells, lymphocytes, macrophages, neutrophils, and eosinophils in BALF was evaluated. Data are means ± SD in each group. Significant different from the mean values in controls without IP, *P < 0·05, **P < 0·005.